Article

Are oestrogens and genetic predisposition etiologic factors in the development of clear cell carcinoma of the peritoneum?

Department of Gynaecological Oncology, Queens Hospital, London, United Kingdom
Medical Hypotheses (Impact Factor: 1.07). 12/2012; 80(2). DOI: 10.1016/j.mehy.2012.11.021
Source: PubMed

ABSTRACT

A literature search was carried out for clinical observations that could explain the possible aetiology of primary peritoneal clear cell carcinoma (CCC) including diagnostic dilemmas, various theories of origin, oestrogen dependence and genetic association. It was found to be an extremely rare tumour (CCC) arising in the peritoneum and is often misdiagnosed as mesothelioma or serous carcinoma or metastatic adenocarcinoma due to overlapping morphological features. The awareness of such dilemmas is important even before making a diagnosis. Clinicopathological features and immunohistochemical studies like WT1, CK20 and calretinin are usually helpful in differentiating CCC from serous carcinoma, metastatic carcinoma from bowel and mesothelioma. (CK7 is common to all epithelial tumours, CEA can be expressed in clear cell carcinoma, WT1 is normally expressed in serous carcinoma, calretinin is expressed in mesothelioma and CK20 in colon carcinoma). The distinction between the above tumours is important as correct diagnosis is required in initiating appropriate treatment. Less than ten cases have been reported in the English language medical literature. Mullerian metaplasia and malignant transformation in endometriosis are two theories proposed for its existence. Peritoneal CCC can be oestrogen dependent in view of association with oestrogen dependent conditions which include endometriosis, adenomyosis and endometrial carcinoma. A genetic ascertain is difficult to be associated and needs further evaluation in a research setting in the familial cancer genetic clinics.

Full-text preview

Available from: sciencedirect.com
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary peritoneal clear cell carcinoma (PP-CCC), which is a rare tumor with poor prognosis, is typically managed with surgery and/or chemotherapy. We present a unique treatment approach for a patient with a pelvic PP-CCC, consisting of postchemotherapy intensity-modulated radiation therapy (IMRT) followed by interstitial high-dose-rate (HDR) brachytherapy. A 54-year-old female with an inoperable pelvic-supravaginal 5.6 cm T3N0M0 PP-CCC tumor underwent treatment with 6 cycles of carboplatin and taxol chemotherapy. Postchemotherapy PET/CT scan revealed a residual 3.3 cm tumor. The patient underwent CT and MR planning simulation, and was treated with 50 Gy to the primary tumor and 45 Gy to the pelvis including the pelvic lymph nodes, using IMRT to spare bowel. Subsequently, the patient was treated with an interstitial HDR brachytherapy implant, planned using both CT and MR scans. A total dose of 15 Gy in 5 Gy fractions over two days was delivered with Ir-192 HDR brachytherapy. The total prescribed equivalent 2 Gy dose (EQD2) to the HDR planning target volume (PTV) from both the EBRT and HDR treatments ranged between 63 and 68.8 Gy2 due to differential dosing of the primary and pelvic targets. The patient tolerated radiotherapy well, except for mild diarrhea not requiring medication. There was no patient-reported acute toxicity one month following the radiotherapy course. At four months following adjuvant radiation therapy, the patient had near complete resolution of local tumor on PET/CT without any radiation-associated toxicity. However, the patient was noted to have metastatic disease outside of the radiation field, specifically lesions in the liver and bone. This case report illustrates the feasibility of the treatment of a pelvic PP-CCC with IMRT followed by interstitial HDR brachytherapy boost, which resulted in near complete local tumor response without significant morbidity.
    No preview · Article · Jan 2014 · Journal of Applied Clinical Medical Physics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe a rare case of metastatic Müllerian tumor originating from the peritoneum assessed by F-FDG-PET/CT. A 52-year-old female patient underwent F-FDG-PET/CT for metabolic characterization of a right pelvic lesion. PET/CT revealed increased F-FDG uptake corresponding to a 3-cm lesion located behind the right anterior pelvic wall. Furthermore, increased F-FDG uptake in a right external iliac lymph node was detected. Based on these F-FDG-PET/CT findings, the patient underwent resection of the pelvic lesion and the right external iliac lymph node. Histology demonstrated a clear cell carcinoma of the Müllerian system originating from the peritoneum with lymph nodal metastasis.
    Full-text · Article · Feb 2014 · Clinical nuclear medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: An 82-year-old male was hospitalized with rectal carcinoma that was confirmed endoscopically. Surgical resection of the rectum was performed. Intraoperative examination showed a solitary hepatic metastasis; metastasectomy was also performed. Histological examination of the surgical specimen showed mainly a trabecular arrangement of the tumor cells, alternating with tubuloglandular areas, the tumor being diagnosed in stage IV. The high-power-view examination showed that the tumor cells presented clear cytoplasm, and were diffusely marked by AE1÷AE3 keratin, carcinoembryonic antigen (CEA), and CD10. A focal immunostain was also observed for keratins 7÷20, vascular endothelial growth factor (VEGF), and its receptor (VEGF-R2). The tumor was proved to be microsatellite stable, presenting K-ras mutation. Based on the immunoprofile and computer scanning, metastases from clear cell renal cell carcinoma and adrenocortical carcinoma have been excluded. Based on these characteristics and the tumor stage, the final diagnosis was primary clear cell adenocarcinoma (CCA). Bevacizumab-based antiangiogenic therapy was indicated. This is the 12th primary CCA of the colorectum ever reported, and the first from Eastern Europe.
    No preview · Article · Sep 2014 · Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Show more